Mechanism of action
Memories are consolidated — not formed — in the hours after trauma. TraumaShield acts on four pathways during that window. Select a pathway to load its model.
Suppress fear learning responses (by reducing the hyper activity in the Amygdala).
Enhances healthy contextual memory (by enhancing hippocampal neuroplasticity).
Enhance GABAergic inhibitory transmission.
View model →Suppress excitatory NMDA receptor activity.
View model →Modulate neuroprotective pathways to prevent long-term damage.
View model →
TraumaShield MDI System
Four components. No electricity. No training. Fits a standard IFAK kit and activates instantly at the point of trauma.
Medical-grade barrier-layered PET. 2-year shelf life. Single-use & disposable. No electricity required.
Controls delivery rate to match respiratory rhythm. Demographically optimized dosing — Child / Adult / Elderly.
Ergonomic seal for rapid application. Instant activation — zero setup required.
Repurposed FDA-approved agent — known safety profile — prevents fear memory consolidation via dual GABA/NMDA mechanism.
47% reduction in PTSD incidence.
Validated. Peer-reviewed. Reproducible.
The neuroscientific mechanism explaining why the 0-6 hour window is the only viable prevention point. Memories are consolidated — not formed — in this window, making pharmacological intervention uniquely effective.
Existing safety profile eliminates Phase 1 risk entirely. The repurposed agent has a well-characterized pharmacokinetic and safety profile from prior clinical use.
Backed by independent peer-reviewed studies. 47% reduction confirmed in human surgical trauma data. Reproducible across preclinical SEFL animal models.
"Backed by independent clinical validation and a full scientific package assembled by world-leading experts in psychiatry and neuroscience."
Protected, fast,
field-ready.
A method-of-use patent, an accelerated regulatory pathway, and a form factor built for the field — three defences that compound.
Exclusive rights secured for the second medical use and combination device architecture.
Streamlined FDA pathway confirmed, leveraging existing safety data to accelerate time-to-market.
Fits standard IFAK kits. Zero training required. Instant activation for immediate post-trauma care.
